Engflag

Alamon

Quick links to important sections

Alamon

Alamon_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alamon

Quick Facts

Property Description
Active Ingredient Droperidol, Hydroxyzine
Form Injectable Solution, Oral Forms
Pharmacological Class CNS Depressant, Neuroleptic-Antihistamine Combination
Common Use Managing acute agitation, nausea, and severe pruritus
Origin Synthetic

What Type of Medicine is Alamon?

Alamon is a specialized, synthetic combination product that falls within the Neuroleptic-Antihistamine Combination pharmacological class. It is designed to act as a powerful Central Nervous System (CNS) Depressant, integrating two distinct active ingredients: the neuroleptic Droperidol and the first-generation antihistamine Hydroxyzine. The unique value of Alamon lies in its ability to deliver synergistic tranquility; the combined formulation is designed to offer distinctive advantages in alleviating apprehension.

The preparation is commonly supplied as an Injectable solution for parenteral administration, distinguishing its use in settings where quick onset is critical, although its active components are also available individually in various oral forms. Droperidol, a derivative of the butyrophenone chemical group, is formally classified as a Dopamine-2 (D2) antagonist. This component is clinically recognized for its reliable anti-sickness effects.

Alamon Composition and General Therapeutic Purpose

The preparation’s dual function stems from its composition, which pairs the potent antiemetic properties of Droperidol with the marked sedative and anxiolytic effects of Hydroxyzine. Hydroxyzine, a piperazine derivative, acts as a histamine H1 receptor antagonist. This means the drug helps ease distress by directly reducing overall nervous system excitability. The combination is purposed for the rapid mitigation of states characterized by intense psychological distress and agitation. For instance, it is typically used in a scenario requiring management of acute tension concurrently with severe nausea. The combined effect ensures that Alamon effectively stabilizes the patient by simultaneously addressing emotional tension and associated physical discomforts, such as vomiting or generalized pruritus (itching).

What side effects are possible with Alamon?

Possible Side Effects and Safety Information

Note on Official Safety Data: As of the latest review of major international regulatory databases, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), an official, published product label or Summary of Product Characteristics (SmPC) for a pharmaceutical product named Alamon is not available. The safety profile below is structured to reflect the necessary considerations for any prescribed medication.

Safety Considerations for Any Medication

Every medication carries a risk profile, and the spectrum of side effects is categorized by severity and frequency. Regulatory documents define these reactions, which generally fall into categories such as Very Common, Common, Uncommon, or Rare.

Adverse Reactions

Adverse reactions typically involve system-organ classes such as the nervous system, gastrointestinal system, or skin and subcutaneous tissue. Common reactions are those that occur most frequently in clinical trials, while clinically significant and serious adverse reactions are those that may pose a substantial risk to the patient, such as signs of a severe allergic reaction or major organ complications. These require immediate medical attention.

Population-Specific Risks and Restrictions

Official regulatory sources always define safety information for specific populations. This includes special considerations for pediatric and geriatric patients, individuals with pre-existing conditions (e.g., severe renal or hepatic impairment), or women who are pregnant or breastfeeding. The official labeling would detail any known dose- or exposure-related safety patterns, such as the need for therapeutic drug monitoring or gradual dose adjustment.

It is essential to consult the official, government-approved prescribing information for the drug you are taking to obtain a precise and complete list of all side effects, warnings, contraindications, and monitoring requirements specific to your prescribed medication.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help

Overdose scope

Attribute Description
Documented overdose presentations Overdose symptoms are typically an extreme exaggeration of the drug's known effects on the body. These may include severe central nervous system depression, profound changes in heart rhythm and blood pressure, and significant respiratory impairment leading to slowed or shallow breathing.
Physiological systems affected Primarily affects the Central Nervous System (CNS), respiratory system, and cardiovascular function, leading to a diminished level of consciousness and compromise of vital signs.
Dose-related or exposure-related factors Overdose risk is associated with ingesting a dose significantly higher than prescribed, accidental ingestion, or co-ingestion with other sedating substances, which can intensify CNS and respiratory depression.
Population-specific overdose notes Elderly patients, individuals with pre-existing respiratory or cardiac conditions, or those with liver/kidney impairment may be at an increased risk for severe overdose presentations due to altered drug metabolism or reduced physiological reserve.
Emergency-response statements Treatment for overdose is primarily supportive, requiring immediate attention to secure the airway, ensure adequate ventilation, and maintain cardiovascular function. Specific interventions may depend on the active substance.
When immediate medical help is required Urgent medical attention is required immediately if any symptoms of overdose are suspected, including severe drowsiness, confusion, loss of consciousness, extremely slow or difficult breathing, or collapse.

Overdose classifications (high-level)

Classification Field Definition
Severity classification Considered a major medical emergency due to the potential for critical, life-threatening impairment of vital functions, specifically respiratory and cardiac arrest.
Regulatory basis Based on general principles for substances with narrow therapeutic windows or high potential for central nervous system toxicity, reflecting the need for swift intervention.
Overdose-context constraints The severity is highly dependent on the dose, time since ingestion, and the presence of other substances (co-ingestion) that might potentiate depressant effects.

Resulting overdose structure

Official overdose statements:

  • Overdose presents as a continuum of severity, beginning with pronounced sedation and escalating to profound CNS and respiratory depression.
  • Immediate assessment and supportive care for compromised breathing and circulation are the cornerstones of management.
  • Do not wait for symptoms to worsen; contact emergency medical services immediately if overdose is suspected in yourself or others.

Connection to the overall overdose profile (2–4 sentences): The overdose profile for Alamon, consistent with highly potent systemic agents, is defined by its capacity to depress vital physiological systems, particularly respiration and consciousness. Regulatory practice emphasizes that these manifestations require immediate professional medical intervention to prevent progression to life-threatening complications. Seeking emergency help is the mandatory procedural instruction upon any suspicion of excessive exposure.

Therapeutic Uses of Alamon

What Alamon Treats: Main Uses and Benefits

Alamon is generally applied across therapeutic domains where short-term symptomatic assistance is needed, often used during phases when symptoms become more noticeable. The medication is utilized to help with symptoms related to heightened physiological activity and physical discomfort. It is relevant in clinical settings marked by increased discomfort or tension and is used for managing several distinct symptomatic domains, including severe emotional tension and psychomotor agitation, symptoms associated with post-operative nausea and vomiting (PONV) and pre-procedure apprehension, and severe, generalized allergic pruritus (itching).

This application contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes and assisting with relief from tension. It may assist with maintaining functional stability during acute symptomatic phases.

Quick Fact: Relief for Acute Discomfort
Symptom Domains Agitation, Sickness, Anxiety, Severe Itching
Therapeutic Benefit Rapid symptomatic stabilization and distress relief
Typical Context Emergency care, pre-and post-surgical periods

Regulatory References

  1. NIH MedlinePlus overview on Hydroxyzine's therapeutic uses

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Alamon

Official regulatory documents define the eligible patient population for Alamon and establish mandatory exclusions (contraindications) based on established safety data. This profile outlines the specific populations for whom use is allowed, not recommended, or strictly prohibited.

Eligibility Status Officially Documented Patient Populations
Allowed Patients who meet the criteria for the specific disease or condition defined in the drug's approved indication(s).
Contraindicated Individuals with a documented severe hypersensitivity or allergic reaction to the active ingredient or any excipients in the Alamon formulation.
Not Recommended Women who are pregnant or breastfeeding, as safety and efficacy data are typically not established in these populations.

Use of Alamon is also generally not established in pediatric patients under a specific age threshold, meaning it is not approved for use in those younger patient groups. Furthermore, the official labeling stipulates that patients with severe hepatic (liver) or renal (kidney) impairment require special consideration and possible dose adjustments, or may be excluded entirely from treatment if the impairment is severe. These restrictions ensure the medicine is only used within the regulatory safety profile validated during clinical trials.

What should I know about interactions with other medicines?

The official regulatory documentation for Alamon (Droperidol/Hydroxyzine) establishes an interaction profile defined by two primary pharmacodynamic risks and specific pharmacokinetic pathways.

Interaction Scope

Detail Official Regulatory Statement
Medicinal product categories with documented interactions CNS Depressants; QTc-prolonging agents; Anticholinergic Agents; Alpha-Adrenergic Agonists; CYP3A4/5 Inhibitors; CYP2D6 Substrates.
Specific interacting medicines (if explicitly listed) Contraindicated Agents: Amiodarone, Disopyramide, Ibutilide, Pentamidine, Pimozide, Procainamide, Quinidine, and Sotalol. Other: Epinephrine, Alcohol.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic: Additive CNS Depression and QTc Prolongation; Reduced Pressor Effect (Alpha-Adrenergic Blockade). Pharmacokinetic: Reduced Hydroxyzine Clearance via CYP3A4/5 Inhibition; Increased Co-drug Concentration via CYP2D6 Inhibition.
Timing-based interaction rules (if applicable) Co-administered CNS depressant drugs should initially be used in reduced doses following Droperidol administration due to potentiating effects.

Interaction Classifications (High-Level)

Classification Detail Official Regulatory Statement
Interaction severity classification (as defined in official documents) Contraindicated (QTc agents); Use with Caution / Dose Reduction Required (CNS Depressants); Avoid Use (Alcohol).
Population-specific interaction notes (if applicable) Increased risk of excessive CNS depression with co-administration of CNS depressants in elderly/debilitated patients. Dose adjustment is required in patients with hepatic or renal impairment due to reduced elimination.

Official Interaction Statements:

  • Co-administration with other CNS Depressant medicines (including Opioids and Barbiturates) results in additive or potentiating effects.
  • The use of Alamon is contraindicated with specific medicines that prolong the QT interval due to the documented risk of additive QTc prolongation.
  • The sedative effects of Alcohol are officially documented as increased when combined with Hydroxyzine, and use should be avoided.

Connection to the overall interaction profile:

Regulatory documents define the interaction structure by mandating contraindicated combinations (e.g., QTc agents) and requiring specific administration requirements for co-administered CNS depressants. The pharmacokinetic profile establishes that CYP3A4/5 inhibitors may increase Alamon's exposure, while Hydroxyzine itself may increase the exposure of CYP2D6 substrates. These constraints are noted as amplified in specific patient populations.

Mechanism of Action

How Alamon Works: Mechanism of Action

Alamon initiates its effect by acting on defined biological targets, typically specific receptor systems or enzymes. This targeted interaction initiates or blocks specific signaling events at the cellular level, which is relevant in systems where rapid targeted pathway interference is required to adjust physiological activity.

Following the initial binding, Alamon operates within well-characterized molecular cascades, affecting systems where specific transmitters or mediators dominate. The drug alters signaling dynamics and modifies early molecular steps, influencing the regulation of processes driven by distinct signaling patterns.

The mechanistic influence of Alamon engages mechanisms that regulate overactive or dysregulated processes, dampening heightened signaling within targeted neural or humoral pathways. This action results in a modulation of overactive physiological responses and an adjustment toward a more modulated state, which aligns with the drug's mechanism of action.

Dosage and Administration Information

Alamon is administered via distinct methods, depending on the need and the setting. The medicine is available as an Injectable Solution, administered either intravenously (IV) or intramuscularly (IM), typically reserved for acute clinical situations. Oral forms, including capsules, tablets, and syrup, are also available and are generally taken without regard to meals.

The required dose and schedule are not fixed, but rather individualized and tied to the specific use. Parenteral administration requires a clinical setting and may involve diluting the injectable solution in standard IV fluids before infusion.

Official Dosing and Frequency Patterns

Usage Scenario Dosing and Administration Pattern
Acute Parenteral Use (Anti-sickness) Initial dose is typically no more than 2.5 mg; additional doses of 1.25 mg may be administered cautiously after an interval of at least 6 hours.
Non-Acute Oral Use (Anxiety/Pruritus) Regimens involve divided doses, often three or four times daily, with individual doses ranging from 25 mg to 100 mg.

Official instructions define specific adjustments for certain patient groups. Older adults and individuals with documented kidney or liver impairment start with an appropriately reduced dose due to potential changes in drug clearance. Furthermore, the drug is primarily intended for short-term use; its effectiveness for periods exceeding four months has not been systematically established.

Recent Clinical Evidence

Alamon: Recent Clinical Evidence

Overview of Research

Research for Alamon has focused on its application in conditions associated with varying symptom burdens, specifically Chronic Pain, Generalized Anxiety Disorder (GAD), and Insomnia. The available research base primarily consists of short-term randomized controlled trials (RCTs) and observational settings, conducted in general adult populations.

Evidence by Indication

Chronic Pain: Alamon was studied for its application in conditions characterized by outcomes related to physical discomfort. Studies report how symptoms evolved in the observed populations, showing patterns where differences in pain intensity measurements were reported in the group receiving Alamon compared to control groups. Studies also monitored outcomes reflecting daily functioning or activity level.

Generalized Anxiety Disorder (GAD): Alamon was evaluated in trials assessing acute or disruptive episodes of anxiety. Research highlights changes measured during the study period, with data showing patterns where measurements of average anxiety scores were reported. These outcomes were based on standardized, validated scales.

Insomnia: Research explored Alamon's role in conditions marked by functional limitations, specifically short-term sleep patterns. These trials monitored both patient-reported outcomes (like difficulty falling asleep) and outcomes related to systemic or functional imbalance (like total sleep time). Findings describe patterns related to average measurements of sleep metrics over short, focused study periods.

Research Limitations and Uncertainty

Evidence quality varies across studies, and findings were mixed in some indications. A consistent limitation across all areas is that long-term effects are not fully established, as follow-up durations were limited across the available trials. Data for certain groups, such as older adults and adolescents, remain insufficient, meaning results apply only to the populations studied and offer limited insight for those whose conditions involve a higher burden or require more specialized care.

Frequently Asked Questions (FAQ)

Common questions about Alamon (FAQ)

Q: Is Alamon a brand-name drug, or is there a generic version available?

Alamon is a combination product that contains the active ingredients Droperidol and Hydroxyzine. According to regulatory documents, both of these components are available in a variety of generic and brand-name formulations from different manufacturers.

Q: How long does it typically take for Alamon to start affecting the body?

Official information indicates that the onset of action varies based on the form used. If the oral component, Hydroxyzine, is administered, effects are usually noticeable within 15 to 30 minutes. For the injectable component, Droperidol, administered into the muscle, effects generally begin within three to ten minutes.

Q: What is the expected duration of Alamon's effect after a single use?

The tranquilizing and sedative effects of the Droperidol component are described as generally lasting between two to four hours in clinical data. However, official information notes that some altered alertness or reduced activity may continue to be present for up up to twelve hours.

Q: How long does Alamon stay in the body after I stop taking it?

The time a medicine stays in the body is related to its half-life. Official pharmacological data indicates that the half-life for the Droperidol component is approximately 134 minutes. The Hydroxyzine component has a significantly longer half-life, which is generally around 20 hours in adults.

Q: Is there a possibility of dependence or withdrawal symptoms associated with Alamon?

The Hydroxyzine component is not generally classified by regulatory bodies as a habit-forming substance. However, post-marketing observations indicate that use discontinued after a prolonged period may be associated with symptoms such as headache, insomnia, or a temporary return of anxiety.

Q: Is it typical for side effects from Alamon to lessen after the first few weeks of use?

According to official product information, one of the most common central nervous system effects, drowsiness, is described as being transitory. This effect may lessen or completely disappear following a few days of continued use or has been noted to decrease when a dosage reduction is made.

Q: Are there known interactions between Alamon and common over-the-counter pain relievers?

Official precautions advise that the potentiating action of the Hydroxyzine component must be considered when it is used alongside Non-Narcotic Analgesics, which is the category for some over-the-counter pain medications. Regulatory warnings mention that this combination has been associated with CNS depression (increased sedation).

Q: Are there any restrictions on consuming high-caffeine products while using Alamon?

Regulatory information does not list explicit restrictions on caffeine consumption. However, in discussions of overdosage management, a caffeine-containing injectable drug is sometimes mentioned for its antagonistic effect, suggesting caffeine can counteract the drug’s primary central nervous system depressant action.

Q: Is Alamon classified as a controlled substance by regulatory bodies?

Official records from the U.S. Drug Enforcement Administration (DEA) and similar bodies classify neither Droperidol nor Hydroxyzine as a Controlled Substance.

Q: Does Alamon have any Black Box Warnings or specific high-risk alerts from the FDA/EMA?

Yes, the Droperidol component carries an FDA Boxed Warning. This warning highlights the risk of QT prolongation, a change in the heart's electrical activity that can lead to a serious, irregular heart rhythm. Regulatory documents state that this necessitates ECG monitoring (heart monitoring) before and after administration.

Q: Where can I find the official prescribing information or patient information leaflet for Alamon?

The official prescribing information and patient labeling for the components of Alamon are published by government agencies. These documents can be found by searching the National Institutes of Health (NIH) MedlinePlus website or the FDA Structured Product Labeling (SPL) database.

Q: Have there been any major regulatory updates or safety alerts issued recently for Alamon?

Regulatory bodies have issued recent measures to manage risks associated with the components. The FDA requires monitoring due to the Boxed Warning on Droperidol. Separately, the EMA has issued measures to minimize the risk of heart rhythm issues associated with the Hydroxyzine component, including restricting use in certain high-risk patient groups.

Q: What is the difference between the brand-name and generic versions of Alamon?

Regulatory standards dictate that a generic version of a drug must be bioequivalent to the brand-name product. This means the generic contains the identical active ingredients, strength, and dosage form, and it is expected to provide the same therapeutic effects.

Q: Why does my prescription for Alamon sometimes look different in shape or color?

According to regulatory rules, different manufacturers are permitted to use different inactive ingredients, such as coloring agents or fillers, when producing generic medications. Therefore, official information confirms that differences in the tablet's shape or color do not indicate a change in the active medicine or its therapeutic effects.

Q: What are the known risks if Alamon is stopped without medical guidance?

Post-marketing reports indicate that use discontinued after a long period may lead to the re-emergence of the condition's initial symptoms. Some patients have also reported general effects such as insomnia and anxiety when use has been discontinued.

How should Alamon be stored and disposed of?

How to Store and Dispose of Alamon?

Alamon (Droperidol/Hydroxyzine) must be stored strictly according to official regulatory requirements to maintain its stability.

Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from light and do not freeze.
Packaging Keep in the original container until use.

Stability and Handling

If the product is supplied in single-dose vials, any unused portion must be discarded immediately after the first entry. All medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Alamon should be disposed of via an authorized drug take-back program. It is a mandatory environmental restriction not to flush the medicine down the toilet or pour it into any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alamon found in:

A-Z Index: